Gastrointestinal Stromal Tumors and Neuroendocrine Tumors

Objectives

Patients with rare gastrointestinal (GI) malignancies can exhibit unique objective and subjective manifestations. This article is a primer for the fundamental understanding of some of these diseases, namely gastrointestinal stromal tumors (GIST) and gastroenteropancreatic neuroendocrine tumors (NET) and therapeutic strategies.

Data Sources

Epidemiologic data, published research reports, national guidelines for oncology practice, and personal experience.

Conclusion

Despite the rarity of GIST, gastroenteropancreatic neuroendocrine tumors, gastric lymphoma, and adenocarcinoma of the small bowel, oncology nurses must be prepared to effectively assess, plan, and implement care strategies for these patients.

Implications for Nursing Practice

Caring for patients with uncommon GI malignancies is challenging for oncology nurses whose experience with these tumors is limited. Fundamental knowledge and awareness of resources can help to ensure optimal patient care. Case vignettes illustrate patient presentation and formulation of treatment recommendations.

Key Words: Gastrointestinal stromal tumors (GIST), gastroenteropancreatic neuroendocrine tumors (NET), carcinoid, imatinib, sunitinib